TON - JUNE 2012 VOL 5, NO 5

TON - JUNE 2012 VOL 5, NO 5 — June 29, 2012

An online chemotherapy therapy education program based on Emmi Solutions is an effective way to educate patients and is a time-saver for oncology nurses, according to nurses from the Hillman Cancer Center at the University of Pittsburgh. They described their program at the 37th Annual Congress of the Oncology Nursing Society held in New Orleans, Louisiana.

Their healthcare system was already using Emmi Solutions in other departments, and based on the success of those programs, the program was introduced into oncology, said Lynda Tunon, RN, MSN, OCN.

Read More ›


TON - JUNE 2012 VOL 5, NO 5 — June 29, 2012

Exercise has been shown to reduce recurrence in men with prostate cancer, according to several studies. A new study shows that vigorous exercise for 1 hour 3 times per week upregulates the expression of genes that are unfavorable to cancer, providing a potential explanation for the mechanism by which exercise has anticancer effects.

Read More ›

TON - JUNE 2012 VOL 5, NO 5 — June 29, 2012

The mighty green spear of the asparagus is a welcome sign of spring. This nutrient-packed vegetable has been harvested for more than 2500 years and has been highly regarded as a promoter of health and wellness.1 Asparagus has been a staple for many different people of different cultures around the world for its taste as well as its proposed medicinal properties. Read More ›


TON - JUNE 2012 VOL 5, NO 5 — June 29, 2012

It’s been a busy time in the world of oncology. The Oncology Nursing Society (ONS) held its 37th Annual Congress in May while the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) took place this month. The Oncology Nurse- APN/PA (TON) was at both events. Our coverage of the news from the ONS and ASCO meetings starts with this issue and will continue over the next several issues.

Read More ›

TON - JUNE 2012 VOL 5, NO 5 — June 28, 2012

Do you remember going to the pediatrician as a child for your vaccinations? Do you ever remember looking at the nurse as she readied the injection and asking her “Is this going to hurt?” Did you ever get back the true answer, something that would go a little like this: “Well, yes, kid, this is going to hurt. After all, usually when a needle sticks through your skin and then a medical substance gets pushed into your body, things kinda hurt. Read More ›


TON - JUNE 2012 VOL 5, NO 5 — June 28, 2012

Brachytherapy after lumpectomy is associated with greater morbidity and need for mastectomy compared with whole-breast radiation, according to a large retrospective study of Medicare claims for older women with early invasive breast cancer (JAMA. 2012;307:1827-1837). Five years after treatment, the rate of mastectomy was twice as high in women treated with brachytherapy versus whole-breast radiation. Both short- and long-term complications were significantly greater in women treated with brachytherapy in this review. Read More ›


TON - JUNE 2012 VOL 5, NO 5 — June 28, 2012

In catching up with breast cancer and several hematologic malignancies, non–small cell lung cancer (NSCLC) has made recent advances in targeting genomic mutations that will provide us with the ability to offer more targeted treatment options. Read More ›


TON - JUNE 2012 VOL 5, NO 5 — June 28, 2012

Although an uncommon cancer, sarcoma, which can arise in various connective tissues and therefore has many subtypes, is a frightening disease for both the young and old. For example, some types of bone cancer occur primarily in children, while others affect mostly adults. As we recognize Sarcoma Awareness Week this month, let’s delve into some statistics surrounding this multifaceted cancer.

Primary bone cancer is rare and accounts for less than 0.2% of all cancers.

Read More ›

TON - JUNE 2012 VOL 5, NO 5 — June 28, 2012

Lower radioiodine doses given with recombinant human thyrotropin (thyrotropin alfa) was as effective as high-dose radioiodine, and the low-dose treatment was associated with fewer side effects. Use of thyrotropin alfa along with low-dose radiation allows patients to avoid fatigue, lethargy, and weight gain associated with thyroid hormone withdrawal. These results suggest that thyroid cancer treatment can be transformed into a safer, shorter session, according to researchers.

Read More ›

Page 1 of 3


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: